Pulmonary hypertension in polymyositis-dermatomyositis: Clinical and hemodynamic characteristics and response to vasoactive therapy

Lupus

Volumn 18, Issue 11, 2009, Pages 1006-1010

  Minai, O A ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

Connective tissue disease; Interstitial lung disease; Polymyositis dermatomyositis; Pulmonary hypertension; Therapy

Indexed keywords

ANTINUCLEAR ANTIBODY; AZATHIOPRINE; BOSENTAN; BRAIN NATRIURETIC PEPTIDE; CORTICOSTEROID; CREATINE KINASE; CYCLOPHOSPHAMIDE; FRUCTOSE BISPHOSPHATE ALDOLASE; JO 1 ANTIBODY; PREDNISONE; PROSTACYCLIN; SILDENAFIL; STEROID; UNIPROST;

ADULT; ARTHRALGIA; ARTICLE; ASTHMA; CASE REPORT; COUGHING; DERMATOMYOSITIS; DOSE RESPONSE; DRUG DOSE INCREASE; DRUG INTERMITTENT THERAPY; DRY SKIN; DYSPNEA; FEMALE; FIBROSING ALVEOLITIS; FUNCTIONAL DISEASE; HAND RASH; HEART CATHETERIZATION; HEMODYNAMICS; HUMAN; HUMAN TISSUE; INTERSTITIAL LUNG DISEASE; INTERSTITIAL PNEUMONIA; LUNG BIOPSY; LUNG FIBROSIS; LUNG FUNCTION TEST; LUNG INFILTRATE; MUSCLE WEAKNESS; OXYGEN CONSUMPTION; PATIENT COMPLIANCE; PERICARDIAL EFFUSION; POLYMYOSITIS; PRIORITY JOURNAL; PULMONARY HYPERTENSION; PULMONARY VASCULITIS; THORAX RADIOGRAPHY; TRANSTHORACIC ECHOCARDIOGRAPHY;

ADULT; CARDIOVASCULAR AGENTS; DERMATOMYOSITIS; FATAL OUTCOME; FEMALE; HEMODYNAMICS; HUMANS; HYPERTENSION, PULMONARY; MIDDLE AGED; SCLERODERMA, SYSTEMIC; VASODILATOR AGENTS;

EID: 70349483953     PISSN: 09612033     EISSN: None     Source Type: Journal    
DOI: 10.1177/0961203309102822     Document Type: Article

References (16)

1. Minai OA, Dweik RA, Arroliga AC. Manifestations of scleroderma pulmonary disease. Clin Chest Med 1998; 19: 713-731.
2. Koh ET, Lee P, Gladman DD, Abu-ShakraM. Pulmonary hypertension in systemic sclerosis: An analysis of 17 patients. Br J Rheumatol 1996; 35: 989-993.
3. Stupi AM, Steen VD, Owens GR, Barnes EL, Rodnan GP, Medsger Jr TA. Pulmonary hypertension in the CREST syndrome variant of systemic sclerosis. Arthritis Rheum 1986; 29: 1515-1519.
4. Bull TM, Fagan KA, Badesch DB. Pulmonary vascular manifestations of mixed connective tissue disease. Rheum Dis Clin North Am 2005; 31: 451-464.
5. Heresi GA, Minai OA. Lupus-associated pulmonary hypertension: Long-term response to vasoactive therapy. Resp Med 2007; 101: 2099-2107.
6. Robbins IM, Gaine SP, Schilz R, Tapson VF, Loyd JE. Epoprostenol for treatment of pulmonary hypertension in patients with systemic lupus erythematosus. Chest 2000; 117: 14-18.
7. Fathi M, Lundberg IE, Tornling G. Pulmonary complications of polymyositis and dermatomyositis. Semin Resp Crit Care Med 2007; 28: 451-458.
8. Caldwell IW, Aitchison JD. Pulmonary hypertension in dermatomyositis. Br Heart J 1956; 18: 273-276.
9. Pace WR, Decker JL,Martin CJ. Polymyositis: Report of 2 cases with pulmonary function studies suggestive of progressive systemic sclerosis. Am J Med Sci 1963; 245: 322-332.
10. Bunch TW, Tancredi RG, Lie JT. Pulmonary hypertension in polymyositis. Chest 1981; 79: 105-107.
11. Grateau G, Roux ME, Franck N, et al. Pulmonary hypertension in a case of dermatomyosists. J Rheumatol 1993; 20: 1452-1453 [letter].
12. Mariette X, Brenot F, Brouet J-C. Recovery from pulmonary hypertension with steroid therapy in a patient with sjogrens syndrome and polymyositis. J Rheumatol 1994; 21: 772-773 [letter].
13. Yaqub S, Moder KG, Lacy MQ. Severe reversible pulmonary hypertension in a patient with monoclonal gammopathy and features of dermatomyositis. Mayo Clin Proc 2004; 79: 687-689.
14. Scheja A, Akesson A, Wollmer P, Wollheim FA. Early pulmonary disease in systemic sclerosis: A comparison between carbon monoxide transfer factor and static lung compliance. Ann Rheum Dis 1993; 52: 725-729.
15. Steen V, Medsger Jr TA. Predictors of isolated pulmonary hypertension in patients with systemic sclerosis and limited cutaneous involvement. Arthritis Rheum 2003; 48: 516-522.
16. Denbow CE, Lie JT, Tancredi RG, Bunch TW. Cardiac involvement in polymyositis: A clinicopathological study of 20 autopsied patients. Arthritis Rheum 1979; 22: 1088-1092.